tiprankstipranks
Advertisement
Advertisement

TSE:DRUG Stock Latest News

Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
The FlyPsychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
11h ago
BMY
CMND
Bright Minds initiated with a Buy at Jefferies
PremiumThe Fly
Bright Minds initiated with a Buy at Jefferies
4d ago
DRUG
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
PremiumRatings
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
18d ago
DRUG
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
PremiumThe Fly
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
1M ago
PBM
ATAI
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
PremiumThe Fly
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
1M ago
DRUG
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
PremiumRatingsCompelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
2M ago
DRUG
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
Premium
Ratings
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
2M ago
DRUG
Bright Minds price target lowered to $126 from $142 at Baird
Premium
The Fly
Bright Minds price target lowered to $126 from $142 at Baird
2M ago
DRUG
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
PremiumCompany Announcements
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
2M ago
6K
DRUG
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
PremiumCompany Announcements
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
3M ago
6K
DRUG
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
PremiumCompany Announcements
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
3M ago
6K
DRUG
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
PremiumThe Fly
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
3M ago
CMPS
DRUG
Bright Minds 1.945M share Secondary priced at $90.00
PremiumThe FlyBright Minds 1.945M share Secondary priced at $90.00
3M ago
DRUG
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
Premium
Company Announcements
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
3M ago
6K
DRUG
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor
Premium
Company Announcements
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor
3M ago
6K
DRUG
Bright Minds price target raised to $142 from $82 at Baird
PremiumThe Fly
Bright Minds price target raised to $142 from $82 at Baird
3M ago
DRUG
Bright Minds price target raised to $147 from $72 at BTIG
PremiumThe Fly
Bright Minds price target raised to $147 from $72 at BTIG
3M ago
DRUG
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline
PremiumCompany Announcements
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline
3M ago
6K
DRUG
Bright Minds Biosciences: Encouraging BMB-101 Efficacy, Pipeline Expansion, and Valuation Upside Support Maintained Buy Rating
PremiumRatings
Bright Minds Biosciences: Encouraging BMB-101 Efficacy, Pipeline Expansion, and Valuation Upside Support Maintained Buy Rating
3M ago
DRUG
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders
PremiumCompany AnnouncementsBright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders
3M ago
6K
DRUG
Bright Minds announces $100M common shares offering
Premium
The Fly
Bright Minds announces $100M common shares offering
3M ago
DRUG
Bright Minds Biosciences: Robust BMB-101 Phase 2 Data and Clear Registrational Path Underpin $115 Target and Buy Rating
Premium
Ratings
Bright Minds Biosciences: Robust BMB-101 Phase 2 Data and Clear Registrational Path Underpin $115 Target and Buy Rating
3M ago
DRUG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >